

Please Direct All Correspondence to Customer Number **20995**

AMENDMENT / RESPONSE TRANSMITTAL

Applicant : Lee, et al.
App. No : 10/009,792
Filed : December 13, 2001
For : ESCHERICHIA COLI STRAIN
SECRETING HUMAN
GRANULOCYTE COLONY
STIMULATING FACTOR (G-CSF)
Examiner : S. Devi
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 25, 2005

(Date)

Suzanne G. Jepson
Suzanne G. Jepson, Ph.D., Reg. No. 51,848

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Amendment in 6 pages.
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Suzanne G. Jepson
Suzanne G. Jepson, Ph.D.
Registration No. 51,848
Agent of Record
Customer No. 20,995
(619) 235-8550



201/645

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lee, et al.
Appl. No. : 10/009,792
Filed : December 13, 2001
For : ESCHERICHIA COLI STRAIN
SECRETING HUMAN
GRANULOCYTE COLONY
STIMULATING FACTOR (G-CSF)
Examiner : S. Devi
Group Art Unit : 1645

CERTIFICATE OF MAILING
I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on
February 25, 2005
(Date)
Suzanne G. Jepson
Suzanne G. Jepson, Ph.D., Reg. No. 51,848

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed November 30, 2004, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Amendments to the Specification begin on page 4 of this paper.

Remarks/Arguments begin on page 5 of this paper.